Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hormel Foods Corp (HRL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Hormel Foods CorpTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Hormel Foods Corp vs IDEXX Laboratories, Inc. — how do they compare? Hormel Foods Corp trades at $24.5 (market cap $13.37B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.5× Hormel Foods Corp's market cap, and Hormel Foods Corp pays a 4.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

HRLIDXX
Market Cap
$13.37B$46.22B
Sector
Consumer StaplesHealth
52-Week High
$29.25$766.68
52-Week Low
$19.74$526.44
Enterprise Value
$15.37B$47.12B
Dividend Yield
4.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hormel Foods Corp

Hormel Foods (HRL) trades at $24.41, down 1.21% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 28.6x and modest 3.8% net margin, while revenue has been stable around $12B annually. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.

HRL offers defensive appeal with consistent dividends and a 4.6% yield, but faces margin pressure and modest growth prospects. Analyst consensus is Hold with a $26.33 price target, suggesting limited upside. Key risks include consumer spending sensitivity and execution challenges under new leadership.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hormel Foods Corp

Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.

Read more on HRL

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX